Targets › CALCRL
5 programs from 3 companies in 24 trials: 12 Phase 3, 5 Phase 4, 4 Phase 1, 3 Phase 2; Neurology, Other, Oncology; next expected readout Nov 2026.
G protein-coupled receptor which specificity is determined by its interaction with receptor-activity-modifying proteins (RAMPs). Together with RAMP1, form the receptor complex for calcitonin-gene-related peptides CALCA/CGRP1 and CALCB/CGRP2. (UniProt, Q16602)
Open in Phaseline: the race on CALCRL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Rimegepant Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 4 | Acute Treatment of Migraine; Menstrual Migraine; Preventive Treatment of Migraine; Pediatric Migraine … | Nov 2026 |
| Amgen | Erenumab Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 3 | Migraine; Posttraumatic Headache; Schwannomatosis | Nov 2026 |
| AbbVie | Ubrogepant Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 3 | Migraine; Healthy Volunteer | May 2027 |
| AbbVie | Atogepant Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 3 | Menstrual Migraine (MM); Episodic Migraine; Chronic Migraine | Jul 2027 |
| Pfizer | Zavegepant (PF-07930207) Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist | RAMP1, CALCRL | Phase 1 | Acute Treatment of Migraine; Migraine | Aug 2027 |
Migraine (9) Acute Treatment of Migraine (4) Vestibular Migraine (2) Menstrual Migraine (MM) (1) Episodic Migraine (1) Chronic Migraine (1) Menstrual Migraine (1) Preventive Treatment of Migraine (1) Pediatric Migraine (1) Healthy Volunteer (1) Posttraumatic Headache (1) Schwannomatosis (1)
small molecule (4), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.